Fabiola Josselyn Torres Padilla

Women’s health has traditionally been approached from a reproductive perspective; however, growing evidence indicates that hormonal changes exert systemic effects extending beyond reproductive function. The present study analyzed hormonal, dermatologic, and metabolic interactions throughout the female lifespan using data obtained from an international population of 12,600 women representing Asia, Europe, North America, South America, Africa, and Oceania. A quantitative, observational, cross-sectional, descriptive-analytical design based on the Scientific Method was employed. Data were collected through anonymous standardized questionnaires that evaluated dermatologic manifestations, metabolic alterations, hormonal changes, and the perceived impact of these conditions on overall health and well-being. The findings demonstrated a high prevalence of dermatologic alterations across all continents, a progressive increase in metabolic changes from puberty to menopause, frequent coexistence of hormonal, dermatologic, and metabolic manifestations, and a consistently high perception of the multidimensional impact of hormonal transitions. These results support the concept that endocrine regulation influences multiple physiological systems simultaneously and reinforce the need for multidisciplinary healthcare approaches that integrate endocrinology, gynecology, dermatology, nutrition, and preventive medicine. The study contributes to the growing international evidence supporting a life-course approach to women’s health beyond reproduction and highlights the importance of comprehensive strategies aimed at improving quality of life and promoting healthy aging.

Cardiometabolic diseases, including obesity, type 2 diabetes mellitus, cardiovascular disease, and heart failure, represent a growing public health challenge throughout the Americas. The increasing prevalence of these conditions has generated interest in therapeutic strategies capable of simultaneously addressing multiple interconnected risk factors. This review aimed to analyze the current scientific evidence regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on heart failure and cardiometabolic risk. A structured literature review based on the Scientific Method was conducted using information obtained from PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, Cochrane Library, and major international clinical guidelines. Evidence from randomized controlled trials, systematic reviews, meta-analyses, and cardiovascular outcome studies was critically evaluated and synthesized. The findings demonstrated that GLP-1 receptor agonists consistently reduce major adverse cardiovascular events, promote significant body weight reduction, improve glycemic control, and contribute to favorable cardiometabolic outcomes. Recent studies also reported improvements in symptoms, functional capacity, and quality of life among patients with obesity-related heart failure with preserved ejection fraction. Additionally, emerging evidence suggests beneficial cardiorenal effects that further support their role within the cardiorenal-metabolic continuum. The clinical relevance of these findings is particularly important for countries such as Mexico, Colombia, and Ecuador, where obesity, diabetes, and cardiovascular disease continue to increase. In conclusion, GLP-1 receptor agonists represent an important advancement in contemporary cardiometabolic medicine and may contribute significantly to integrated prevention and management strategies aimed at reducing cardiovascular and metabolic disease burden across the Americas.

Advanced thyroid cancer remains a significant clinical challenge despite major advances in endocrine oncology. Although conventional management based on surgery and radioactive iodine therapy continues to provide favorable outcomes for many patients, locally advanced, recurrent, metastatic, and radioiodine-refractory disease often require more complex therapeutic approaches. The objective of this review was to analyze contemporary surgical innovations, molecular-targeted therapies, and nuclear medicine strategies used in the management of advanced thyroid cancer throughout the Americas. A narrative literature review was conducted using the Scientific Method as the methodological framework. Scientific evidence was retrieved from PubMed, Scopus, Web of Science, ScienceDirect, Cochrane Library, and Google Scholar, focusing on studies published between 2014 and 2026. The findings demonstrated that molecularly targeted therapies have become a central component of treatment, particularly in tumors harboring BRAF, RET, and NTRK alterations. Lenvatinib, sorafenib, cabozantinib, selpercatinib, pralsetinib, and dabrafenib-trametinib have significantly expanded therapeutic options for patients with advanced disease. Surgical intervention remains essential for local disease control and management of recurrent or invasive tumors, while nuclear medicine continues to play a critical role through radioactive iodine therapy, PET/CT, SPECT/CT, and emerging redifferentiation strategies. The review also identified important challenges related to molecular testing accessibility, targeted therapy availability, specialized surgical services, and nuclear medicine infrastructure across different healthcare systems. Overall, the evidence supports a transition toward precision medicine and multidisciplinary management as the foundation of contemporary advanced thyroid cancer care. Continued efforts to improve access to innovative technologies and specialized treatment resources will be necessary to optimize patient outcomes throughout the American continent.